[ad_1]
Dublin, July 30, 2021 /PRNewswire/– “Humira? (Adalimumab) biosimilars: focus on approved and launched biosimilars, research and research using biosimilars, inactive/terminated/withdrawn biosimilars, industry/non-industry partners relation” Report has been added to ResearchAndMarkets.com supply.
“Adalimumab Biosimilars: Focus on approved and launched biosimilars, research and research using biosimilars, inactive/terminated/withdrawn biosimilars, industry/non-industry partnerships” report on current development Extensive research has been conducted on the user pattern and all relevant clinical research scenarios. The follow-up products of the heavyweight biological drug HUMIRA, which are either available or under development.
The information in this report is presented through two deliverables, an Excel table with an interactive dashboard and a PowerPoint presentation that summarizes ongoing activities in the field and key insights derived from the available data.
Considering the number of indications it is eligible to treat, and it is the first of its kind, HUMIRA quickly gained blockbuster status; Abbott Laboratories reports global sales $1.4 billion Products in 2005. HUMIRA’s market performance reached its peak in 2018, reaching $19.9 billion In product sales revenue.However, since the first batch of biosimilars were officially launched Europe In the same year, the market share of original research products has been declining, but at a slower rate.
With a relatively large intellectual property portfolio and an active legal strategy, AbbVie has been very successful in preventing Adalimumab from entering the global market. This…
The full story on Benzinga.com
[ad_2]
Source link
